Actively Recruiting
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
Led by Washington University School of Medicine · Updated on 2025-06-10
60
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
CONDITIONS
Official Title
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female of any race
- Age 18 years or older
- Healthy volunteers or volunteers with Alzheimer's disease
You will not qualify if you...
- Allergy to 18F-Fluselenamyl or its components
- Allergy to 11C-PIB or its components
- Unable to provide informed consent or no authorized representative
- Unwilling or unable to have PET scan tracer injections
- Unwilling or unable to have MRI (for Aim 2 and Aim 3)
- Any condition increasing risk or interfering with study (e.g., kidney or liver failure, advanced cancer)
- Currently pregnant or breastfeeding
- Participation in other research with radioactive agents exceeding yearly radiation limits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
J
Jayashree Rajamanickam
CONTACT
K
Kelley Jackson
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here